White blood cell (WBC) ? 50 × 10^3/?LXx_NEWLINE_xXWhite blood cells (WBC) > 3 x 10^9/L, within 28 days prior to administration of study treatmentXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood count >= 3,000/uL, obtained within 4 weeks prior to randomizationXx_NEWLINE_xXWhite blood cell count (WBC) >= 2,000/mcL; must be obtained within 28 days prior to registrationXx_NEWLINE_xXWhite Blood Cell Count (WBC) Criteria\r\n* Age 1-9.99 years: WBC >= 50 000/uL \r\n* Age 10-30.99 years: Any WBC \r\n* Age 1-30.99 years: Any WBC with:\r\n** Testicular leukemia\r\n** CNS leukemia (CNS3)\r\n** Steroid pretreatmentXx_NEWLINE_xXWhite blood cells >= 2000/uL, within 4 weeks of randomizationXx_NEWLINE_xXWhite blood cell count >= 4000 cells/mm^3Xx_NEWLINE_xXFor patients with AML or MDS, patient must have white blood cell count (WBC) ? 50,000/mL. Hydroxyurea is allowed to achieve this change but must be discontinued a minimum of five (5) days prior to baseline evaluationXx_NEWLINE_xXWhite blood cells (WBC) > 3 x 10^9/L, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) orXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cell count >= 2.5 x 10^3/mm^3Xx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Circulating white blood cell (WBC) count must not be above 20 x10^9/L within 7 days prior to first dose of study agent\r\n* Patients with WBC count above 20 x 10^9/L may be eligible if they start steroids or hydroxyurea per institutional guidelines, but they must discontinue before day 1 of study drugXx_NEWLINE_xXWhite blood cell (WBC) count ? 3 × 10e3/µLXx_NEWLINE_xXMeasured within 28 days prior to registration: white blood cells > 3,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) >= 2.0 x 10^9/LXx_NEWLINE_xXMore than 5% white blood cells in bone marrow.Xx_NEWLINE_xXWhite blood cells (WBC) > 15,000 cells/mcL (15 cells x 10^9/L) at screening. In subjects with WBC > 15,000 cells/mcL at screening with lymphocyte predominance, subject may be deemed eligible for the trial by the Amgen physician, after discussion with the investigator.Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/uLXx_NEWLINE_xXCOHORT 1: White blood cell (WBC) count =< 30,000 /mcL within 14 days of treatment initiation\r\n* NOTE: Hydroxyurea/leukapheresis use is allowed to meet this criterionXx_NEWLINE_xXCOHORT 2: White blood cell (WBC) count =< 30,000 /mcL within 14 days of treatment initiation\r\n* NOTE: Hydroxyurea/leukapheresis use is allowed to meet this criterionXx_NEWLINE_xXWhite blood cells (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) >= 2,000/mm^3, performed within 14 days of treatment initiationXx_NEWLINE_xXWhite blood cells (WBC) > 3 x 10^9/LXx_NEWLINE_xXWBC =< 3 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) greater than or equal to 3,000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite Blood Cell Count (WBC) > 3,000/µLXx_NEWLINE_xXObtained within 14 days prior to course 1 day 1 (C1D1): White blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhile blood cells 2000/ul or moreXx_NEWLINE_xXTotal white blood cells (WBC) < 2x10^9/L (2000/mm^3)Xx_NEWLINE_xXWhite blood cells (WBC) < 4,000Xx_NEWLINE_xXWhite blood cell count (WBC) < 2,000/µLXx_NEWLINE_xXWhite Blood Cell (WBC) ?2000/?L (?2 x 10^9/L)Xx_NEWLINE_xXWhite blood cells (WBC) >= 3 x 10^9/L, completed within 14 days prior to the date of registrationXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells >= 3,000/microliterXx_NEWLINE_xXWhite blood cell (WBC) ? 3.00 K/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) > 2,000/mcLXx_NEWLINE_xXWhite blood cell count (WBC) > 2500/uLXx_NEWLINE_xXWhite blood cells (WBC) > 15,000 cells/mcL at screeningXx_NEWLINE_xXWhite blood cell (WBC) count >= 3,000/mcLXx_NEWLINE_xXWhite blood cell count (WBC) > 2500 cells/mm^3Xx_NEWLINE_xXWhite blood cells (WBC) >= 2,500/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXPatients who have a white blood cell count less than 2,500 per cubic mmXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) > 3500/ul within four weeks of enrollmentXx_NEWLINE_xXWhite blood cell count (WBC) >= 3.0 K/mm^3Xx_NEWLINE_xXPART I: White blood cell (WBC) >= 2,500 cells/mm^3Xx_NEWLINE_xXPART II: WBC >= 2,500 cells/mm^3Xx_NEWLINE_xXwhite blood cell (WBC)count >= 3,000/mm3.Xx_NEWLINE_xXWhite blood cells (WBC) >= 2.5Xx_NEWLINE_xXWhite blood cell (WBC) count >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uL.Xx_NEWLINE_xXWithin 14 days of randomization: White blood cell (WBC) count >= 3 x 10^9/LXx_NEWLINE_xXWithin 14 days of the first dose of study drug: White blood cells (WBCs) >= 2000/uLXx_NEWLINE_xXWBC < 2,000 uLXx_NEWLINE_xXWhite blood cell (WBC) count >= 3 × 10^9/L.Xx_NEWLINE_xXWhite blood cells (WBC) > 2,500/mcLXx_NEWLINE_xXSubject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion.)Xx_NEWLINE_xXSubject has a white blood cell count > 25 × 109/L; note: hydroxyurea is permitted to meet this criteriaXx_NEWLINE_xXWhite blood cell (WBC) < 3,500/mm^3Xx_NEWLINE_xXWhite blood cell count (WBC) >= 2000/uL.Xx_NEWLINE_xXWhite blood cell (WBC) count >= 3 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) count >= 3 x 10^9/L (in absence of blood transfusion).Xx_NEWLINE_xXWhite blood cell (WBC) ? 1,500/mcLXx_NEWLINE_xXWhite blood cell count ? 10,000Xx_NEWLINE_xXPatients receiving other active treatment for their myeloid malignancy including investigational agents with the exception of hydrea for white blood cell (WBC) controlXx_NEWLINE_xXObtained within 14 days prior to randomization/registration: white blood cell (WBC ) >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) > 2,000/dl (or absolute neutrophil count [ANC] > 1,000)Xx_NEWLINE_xXWithin 28 days prior to administration of study treatment: White blood count (WBC) > 3 x 10^9/LXx_NEWLINE_xXParticipant has a white blood cell count > 25 × 10^9/L. (Hydroxyurea or leukapheresis are permitted to meet this criterion.)Xx_NEWLINE_xXPatients with white blood cell (WBC) > 30,000 are not eligible to start therapy; however, it is permissible to use glucocorticoids and/or hydroxyurea to diminish peripheral WBC to less than 30,000 provided these agents are stopped at least 24 hours prior to the first dose of MLN0128 (TAK-228)Xx_NEWLINE_xXWhite blood cell count >= 2.0 x 10^9/LXx_NEWLINE_xXWhile blood cells 2000/ul or moreXx_NEWLINE_xXWhile blood cells 2000/ul or moreXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uL.Xx_NEWLINE_xXWhite blood cell (WBC) count < 50,000/uL before administration of pevonedistat on cycle 1 day 1; Note: hydroxyurea may be used to control the level of circulating leukemic blast cell counts to not lower than 10,000/uL during the studyXx_NEWLINE_xXWhite blood cell (WBC) >= 2,500 cells/uLXx_NEWLINE_xXObtained within 14 days of the first study treatment: White blood cell (WBC) count > 2500/uLXx_NEWLINE_xXWhite blood cell count > 3 K/uLXx_NEWLINE_xXWhite blood cell count > 3 K/uL.Xx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell count >= 2000/uLXx_NEWLINE_xXLeukocytes (white blood cells [WBCs]) >= 3,000/uL.Xx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uL within 14 days of registrationXx_NEWLINE_xXWithin 7 days prior to administration of study treatment: White blood cells (WBC) > 3 x 10^9/L.Xx_NEWLINE_xXWhite blood cell count (WBC) >= 2.5 k/mm^3Xx_NEWLINE_xXWhite blood cells (WBCs) >= 2000/microL within 14 days of study registration.Xx_NEWLINE_xXObtained within 21 days prior to randomization/registration: White blood cell (WBC) >= 2000/uL.Xx_NEWLINE_xXObtained within 14 days of the first study treatment: White blood cell (WBC) count > 2500/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 3 x 10^9/L.Xx_NEWLINE_xXSubject has a white blood cell count > 25 x 10{Xx_NEWLINE_xXWhite blood cell count > 2500/uLXx_NEWLINE_xXWhite blood cell (WBC) < 2.0 x 10^9/L (or absolute neutrophil count < 1000)Xx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uLXx_NEWLINE_xXTotal white blood cell count (WBC) >= 2,000 cells/mm^3 without growth factors within 1 week of the initiation of treatmentXx_NEWLINE_xXWhite blood cell (WBC) >= 3 x 10^9 cells/mLXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1): white blood cell (WBC) counts > 2500/uLXx_NEWLINE_xXSTUDY TREATMENT: White blood cells (WBC) >= 2000/ulXx_NEWLINE_xXWhite blood cells (WBC) > 3 x 10^9/LXx_NEWLINE_xXLeukocytes (white blood cell [WBC]) >= 3,000/uLXx_NEWLINE_xXPatients with AML whose white blood cell count exceeds 25,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood cell count (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXwhite blood cell count (WBC) ? upper limit of normal (ULN);Xx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uL, within 30 days before study registrationXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uL within 14 days prior to first doseXx_NEWLINE_xXWhite blood count (WBC) >= 2000/mcL, performed within 14 days of protocol registrationXx_NEWLINE_xXWhite blood cells (WBC) >= 3 x 10^9 cells/mLXx_NEWLINE_xXWhite Blood Cell (WBC) ? 2500 cells/mm3Xx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXObtained within 14 days of randomization: White blood cells (WBCs) >= 2000/uLXx_NEWLINE_xXParticipant has a white blood cell count > 25 × 109/L. (Note: Hydroxyurea administration or leukapheresis is permitted to meet this criterion).Xx_NEWLINE_xXWhite blood cell (WBC) < 2,000/mm^3Xx_NEWLINE_xXPeripheral white blood cell count < 50,000/mcl (patients may receive hydroxyurea as necessary for cytoreduction)Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) within 10% of upper and lower limit of normal range of testXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/mm^3Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uLXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uLXx_NEWLINE_xXPerformed within 14 days (+ 3 working days) prior to registration: White blood cell (WBC) > 3,000/ul.Xx_NEWLINE_xXWhite blood cells (WBC)\t>= 2,000/uLXx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 2500 cells/uL (obtained within 28 days prior to first study treatment)Xx_NEWLINE_xXWithin 14 days of registration: White blood cell (WBC) > 3 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uL within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXThe use of hydroxyurea before enrollment is permitted; hydroxyurea should be discontinued prior to start of study treatment; patients with symptoms/signs of hyperleukocytosis or white blood cell count (WBC) >100,000/uL can be treated with leukapheresis or may receive up to 1 dose of cytarabine (up to 500 mg/m^2) anytime prior to enrollmentXx_NEWLINE_xXWhite blood cell (WBC) > 50,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) count >= 3,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXCirculating white blood cells < 25.1000000000 /L (with or without use of hydroxycarbamide).Xx_NEWLINE_xXWhite blood cells (WBC) =< 10 x 10^9/LXx_NEWLINE_xXWhite blood cell count (WBC) >= 2000/uL should be obtained within 21 days prior to enrollmentXx_NEWLINE_xXWhite blood cell count (WBC) > 3 x 10^9/LXx_NEWLINE_xXWhite blood cells (WBC) > 3,000 cells/mm^3Xx_NEWLINE_xXPatients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollmentXx_NEWLINE_xXDisease status allows delay of additional anti-leukemia therapy for the duration of the study (hydroxyurea is allowed for control of white blood cell count [WBC] throughout study)Xx_NEWLINE_xXWBC ?2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2000 /uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2,000/mcLXx_NEWLINE_xXWhite blood cells (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood cell count (WBC) ? 3.0 x 109/LXx_NEWLINE_xXWhite blood cells (WBC) >= 3 x 10^9 cells/mlXx_NEWLINE_xXWhite blood cells (WBC) =< 10,000/uLXx_NEWLINE_xXThe use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to study day 0 enrollmentXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cell count (WBC) >= 2500/mm^3Xx_NEWLINE_xXWhite blood count < 30,000/uLXx_NEWLINE_xXWhite blood cell (WBC) of 2,000 per microliter (mcL)Xx_NEWLINE_xXWhite blood cell count (WBC)\t>= 2,000 /mcLXx_NEWLINE_xXWhite blood cell count >= 3,500 cells/mm^3Xx_NEWLINE_xXWhite blood cell >= 2,500 cells/ul without growth factor supportXx_NEWLINE_xXWhite blood count (WBC) >= 2000/uL obtained within 14 days prior to randomization/registrationXx_NEWLINE_xXWhite blood cells (WBC) < 200/mclXx_NEWLINE_xXWhite blood cell count > 2,500 cells/mcLXx_NEWLINE_xXWhite blood cell count (WBC) >= 2.0 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) count at randomization less than or equal to (</=) 50000 cells per cubic millimeter (/mm^3)Xx_NEWLINE_xXWhite blood cell counts (WBC) > 2500/uLXx_NEWLINE_xXWhite blood cell >= 2000/uLXx_NEWLINE_xXWithin 14 days prior to study entry: White blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWithin 6 weeks of day 1: White blood cells (WBC) >= 2000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mm3Xx_NEWLINE_xXWhite blood cells (WBC) > 3x10^9/L (measured within 28 days prior to administration of study treatment)Xx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA: \r\nWhite blood cell (WBC) >= 3,000/mcLXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nWhite blood cell (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) > 3.0 x 10^9/L within 14 days of study entryXx_NEWLINE_xXWhite blood cell (WBC) < 2,500/mm^3Xx_NEWLINE_xXDocumented white blood cell count of >= 3,000Xx_NEWLINE_xXWhite blood cell count (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) count > 2500/uLXx_NEWLINE_xXPresence of active central nervous system (CNS) leukemia - cerebrospinal fluid (CSF) with < 5 white blood count (WBC)/uL will not exclude the patientXx_NEWLINE_xXWhite blood cells (WBC) > 3.0Xx_NEWLINE_xXMust be met within 28 days of course 1 day 1 (C1D1): White blood cell (WBC) >= 2,000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000/mm^3Xx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: White blood cell count (WBC) >= 2,000/uLXx_NEWLINE_xXWhite blood cells (WBC) < 3.5 K/mcLXx_NEWLINE_xXWhite blood cells (WBC) >= 2500/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/LXx_NEWLINE_xXWhite blood cell (WBC) > 2,000/dl orXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapyXx_NEWLINE_xXWhite blood cells (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) > 2000/mm^3Xx_NEWLINE_xXa. WBC > 3,000/µLXx_NEWLINE_xXWhite blood cell count (WBC) > 4000/mm^3Xx_NEWLINE_xXWhite blood cells (WBC) is >= 1500/ulXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2,000/uLXx_NEWLINE_xXPatients must have lymphocytosis with white blood cells between 30,000-100,000/uL in order to collect adequate leukemia cells for vaccine productionXx_NEWLINE_xXAny form of primary or secondary immunodeficiency; must have recovered immune competence after chemotherapy or radiation therapy as evidenced by lymphocyte counts (> 500/mm^3), white blood cell (WBC) (> 3,000/mm^3) or absence of opportunistic infections (Turnstile II)Xx_NEWLINE_xXWhite blood cell (WBC) < 4,000Xx_NEWLINE_xXWhite blood cells (WBC) >= 3.0Xx_NEWLINE_xXWhite blood cell (WBC) >= 2,500 cells/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/LXx_NEWLINE_xXWhite blood cell count >= 1000/ul (phase I only)Xx_NEWLINE_xXAny form of primary or secondary immunodeficiency; must have recovered immune competence after chemotherapy or radiation therapy as evidenced by lymphocyte counts (> 500/mm^3), white blood cell (WBC) (> 3,000/mm^3) or absence of opportunistic infections (Turnstile II)Xx_NEWLINE_xXWhite blood cell (WBC) with differential greater than 3,000/mlXx_NEWLINE_xXWhite blood cells (WBC) >= 3.0Xx_NEWLINE_xXWhite blood cell >= 3500/ulXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood count (WBC) > 2,500/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 4,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3.0 x 10^9/L (performed within 14 days prior to registration)Xx_NEWLINE_xXWhite blood cell count >= 1000/ulXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 4000/mm^3Xx_NEWLINE_xXWhite blood cells (WBC) >= 4000/mm^3Xx_NEWLINE_xXWhite blood cell count (WBC) > 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 2,000/ulXx_NEWLINE_xXWhite blood cell (WBC) count >= 3,500/mm^3 within 7 days prior to starting treatment, ORXx_NEWLINE_xXAny form of primary or secondary immunodeficiency; must have recovered immune competence after chemotherapy or radiation therapy as evidenced by lymphocyte counts (> 500/mm^3), white blood cell (WBC) (> 3,000/mm^3) or absence of opportunistic infections (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)Xx_NEWLINE_xXWhite blood cell count >= 2.5 x 10^3/mm^3Xx_NEWLINE_xXWhite blood cell count >= 2.5 x 10^3/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) count 3,000/mLXx_NEWLINE_xXHemoglobin level greater than (>) 10 gram per deciliter (g/dL) (following blood transfusion is acceptable) and normal white blood cell (WBC) and neutrophil counts (elevated WBC/absolute neutrophil count [ANC] attributed to steroid treatment is acceptable)Xx_NEWLINE_xXWhite blood count ? 3500 cells/mm3Xx_NEWLINE_xXWhite blood cell count ? 2000/?LXx_NEWLINE_xXWhite blood cells (WBC) >= 3 x 10^3/ulXx_NEWLINE_xXWhite blood cell count (WBC) >= 3.5K/mm^3Xx_NEWLINE_xXWhite blood cells (WBC) >= 2,500/mm^3Xx_NEWLINE_xXPatients with uncontrolled white blood cell count (defined as > 50 K/cu mm not controlled with hydrea).Xx_NEWLINE_xXThe use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollmentXx_NEWLINE_xXWhite blood cell count (WBC) t ? 2.5 x 109/L (2500/µL)Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts >= 2500/uL.Xx_NEWLINE_xXWithin 14 days prior to first dose of study drug treatment: White blood cell (WBC) >= 2.5 and =< 15.0 x 109/LXx_NEWLINE_xXWhite blood cell (WBC) ? 3500 cells/mm^3 ? 2 weeksXx_NEWLINE_xXDONORS: White blood cells (WBC) within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)Xx_NEWLINE_xXReceipt of any anti-cancer therapy within 14 days prior to study entry, with the exception of hydroxyurea; if clinically indicated in order to keep white blood cells (WBC) < 30,000/uL, hydroxyurea may be continued through the first cycleXx_NEWLINE_xXWBC (white blood cell count) is 2000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3.0 x 10^3/ulXx_NEWLINE_xXWhite blood cell (WBC) less than or equal to 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXTotal absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least 1000/uLXx_NEWLINE_xXWhite blood count >= 3,000/uLXx_NEWLINE_xXPerformed within 14 days prior to study: White blood count (WBC) > 3,000/ulXx_NEWLINE_xXWhite blood cells (WBC) >= 2,000/mcLXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells 2000/ul or moreXx_NEWLINE_xXWhite blood cell count >= 3,000 /ulXx_NEWLINE_xXObtained within 30 days prior to registration: White blood cell (WBC) >= 2 k/mm^3Xx_NEWLINE_xXWhite blood cell count (WBC) >= 3 x 10^9/LXx_NEWLINE_xXWhite blood count > 3,000/mcLXx_NEWLINE_xXStep 2: White blood count > 3,000/mcLXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; treatment with hydroxyurea is permitted during cycle 1 to maintain white blood cell (WBC) < 40,000/uLXx_NEWLINE_xXWhite Blood Cell count (WBC) < 4,000/µLXx_NEWLINE_xXTotal white blood cell count ?200,000/mm3Xx_NEWLINE_xXScreening urinalysis < 5 white blood cell/high power field (WBC/hpf) (unless alternate urinary diagnosis not consistent with infection)Xx_NEWLINE_xXWhite blood cell (WBC) >= 2.0 x 10^3/ulXx_NEWLINE_xXWBC >= 2.0 x 10^3/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3500/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 4000/mlXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uLXx_NEWLINE_xXWhite blood cell (WBC) count >= 50,000 on hydroxyureaXx_NEWLINE_xXDONOR: White blood cells (WBC), platelet count near normal limits (± 10%)Xx_NEWLINE_xXWhite blood count >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 2,500 cells/uLXx_NEWLINE_xXWhite blood cells (WBC) > 3 x 10^9/L, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXWhite blood cell (WBC) > 3500/ulXx_NEWLINE_xXWhite blood cell (WBC) > 3,000/mcL orXx_NEWLINE_xXWhite blood cell (WBC) > 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 2,000 cells/uLXx_NEWLINE_xXWhite blood cells (WBCs) >= 2000 cells/uLXx_NEWLINE_xXNo exclusion for blood counts; however, at the time of treatment initiation, white blood cell (WBC) should be < 30,000/uL (can be controlled with hydroxyurea)Xx_NEWLINE_xXWhite blood cell count (WBC) >= 3500/ulXx_NEWLINE_xXWhite blood cell (WBC) > 2,000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000Xx_NEWLINE_xXWhite blood count (WBC) > 2.5 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) greater than or equal to 3,000/ulXx_NEWLINE_xXWBC ?3,000/µlXx_NEWLINE_xXTotal white blood cell count (WBC) > 2000/mcLXx_NEWLINE_xXWhite blood cells (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXSubject has a white blood cell count > 25 × 10^9/L. Note: Hydroxyurea is permitted to meet this criterion.Xx_NEWLINE_xXWhite Blood Cell Count value of <15,000 cells/?L prior to Cycle 1 Day 1.Xx_NEWLINE_xXAbsolute White blood cell (WBC) count ? 15 × 109/L (NOTE: Hydroxyurea is not allowed to attain a WBC count ? 15 x 109/L).Xx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWBC ? 2,500/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) > 2,500 cells/mm^3Xx_NEWLINE_xXWhite blood cells (WBC) > 3,000/mcLXx_NEWLINE_xXWhite blood cell count > 25 x 10e9/L or > 10% peripheral blood blasts;Xx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000 cells/mcLXx_NEWLINE_xXB-ALL patients must have an initial white blood cell count < 50,000/uLXx_NEWLINE_xXWhite blood cell (WBC) count >= 2500/ul, obtained within 14 days prior to initiation of study treatmentXx_NEWLINE_xXWhite blood cells (WBCs) >= 2000 cells u/LXx_NEWLINE_xXWhite blood cells (WBCs) >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,500/mcLXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) count >= 3.0 x 10^9/LXx_NEWLINE_xXDocumentation of keratosis follicularis (also known as Darier or Darier-White disease)Xx_NEWLINE_xXThe use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollmentXx_NEWLINE_xXWhite blood cells (WBCs) >= 2000/uLXx_NEWLINE_xXPatients with a white blood cell count of more than 30 x 10^3 K/uL will not be eligible for this studyXx_NEWLINE_xXWhite blood cell (WBC) count >= 3.0 x 10^9/LXx_NEWLINE_xXThere are no minimum hematological parameter requirements prior to the first two cycles, as patients with AML and myelodysplastic syndrome (MDS) are understood to have low ANC and platelet counts when the disease is active; however, patients with white blood cell (WBC) greater than 50,000 will receive hydroxyurea to reduce the WBC count to below 50,000 at which point they may begin treatmentXx_NEWLINE_xXMantle cell lymphoma International Prognostic Index (IPI) (MIPI) score must be calculated and entered in Oncology Patient Enrollment Network (OPEN)\r\n* NOTE: for this calculation white blood cell (WBC) 7,500/mm^3 = 7,500/uL = 7.5 x 10^9/L should be entered as 7500Xx_NEWLINE_xXWhite blood cell (WBC) count >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood count (WBC) >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell count (WBC) >= 4,000/mlXx_NEWLINE_xXWhite blood cell (WBC) count >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) count ? 3 × 10e3/µLXx_NEWLINE_xXWhite blood cells (WBC) > 3.0 mlXx_NEWLINE_xXPrior to cyclophosphamide and T cell infusions: white blood cells (WBC) =< 2000/uLXx_NEWLINE_xXWhite blood cell count >= 2000/uL, obtained =< 21 days prior to registration and confirmed prior to the first dose of study drugXx_NEWLINE_xXWithin 14 days prior to registration: white blood cells (WBC) >= 2,000/uLXx_NEWLINE_xXWhite blood cells (WBC) > 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 4200/mm^3Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): White blood cells (WBC) counts > 2500/uLXx_NEWLINE_xXWhite blood cells (WBCs) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) > 3500/ulXx_NEWLINE_xXWhite blood cells (WBC) < 2,000/ulXx_NEWLINE_xXWhite blood cells (WBC) >= 2500 cells/ulXx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000/mm^3Xx_NEWLINE_xXParticipant has a white blood cell count greater than 25 × 10^9/L. Hydroxyurea is permitted to meet this criterion.Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) > 2,000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000 cells/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2500/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/ulXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cells (WBC) =< 1000/uLXx_NEWLINE_xXCOHORT A: White blood cells (WBC) >= 2000/uLXx_NEWLINE_xXCOHORT B: WBC >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3.0 x 10^9 cells/LXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1); white blood cell (WBC) counts > 2500/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) must be > 3500 cells/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/ulXx_NEWLINE_xXWhole blood cell (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cell count > 2,500/mcLXx_NEWLINE_xXWhite blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/LXx_NEWLINE_xXUse of investigational agents/any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea (NOTE: for patients with hyperleukocytosis [white blood cell (WBC) > 20,000/uL], hydroxyurea [and leukapheresis, if clinically indicated] will be initiated and these patients will receive 5-azacytidine when the WBC count has decreased to =< 20,000/uL; hydroxyurea can be overlapped with 5-azacytidine in selected cases, after consultation with the study chair; hydroxyurea must be discontinued before the initiation of the HiDAC/mitoxantrone chemotherapy)Xx_NEWLINE_xXWhite blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/LXx_NEWLINE_xXWhite blood cells (WBC) < 2.0Xx_NEWLINE_xXPatients with peripheral blood involvement with white blood count (WBC) > 20,000 or those considered to be at high risk for tumor lysis syndrome (TLS) by high tumor burden are EXCLUDED for the Phase I component of the studyXx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: white blood cells (WBC) >= 3,000/mm^3 within 3 weeks of study entryXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/mm^3Xx_NEWLINE_xXPeripheral white blood cell count =< 50,000/mclXx_NEWLINE_xXWhite blood cell count >= 1000/ulXx_NEWLINE_xXWhite blood cell (WBC) count >= 3.0 x 10^9/LXx_NEWLINE_xXObtained within 14 days prior to registration: White blood cells (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cell (WBC) = 2500 mm^3Xx_NEWLINE_xXDONOR: Donors must have a white blood cell count > 3.5 x 10^9/literXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWBC at least 3,000/mm3Xx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) <2,000/mm3Xx_NEWLINE_xXWhite blood cells (WBC): >= 2000/uL (~ 2 x 10^9/L)Xx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cells (WBC) > 2.0 K/uLXx_NEWLINE_xXPatients receiving hydroxyurea may continue receiving it for up to 14 days after the start of protocol treatment if white blood cells (WBC) > 30 x10^9/LXx_NEWLINE_xXEXPANSION COHORT ONLY: White blood cell (WBC) >= 3,00/mm^3Xx_NEWLINE_xXWBC >= 3,000/ulXx_NEWLINE_xXWhite blood cells (WBC) < 2,500/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) counts > 2500/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])Xx_NEWLINE_xXWithin 14 days prior to enrollment/randomization: White blood cells (WBC) >= 3.0 K/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2.0 x 10^3/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 2.0 x 10^3/uLXx_NEWLINE_xXWhite blood count (WBC) >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) > 1000/mm^3Xx_NEWLINE_xXDONOR: White blood cell count of >= 3,000Xx_NEWLINE_xXWhite blood count >= 3,000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) > 2000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) > 2000/uLXx_NEWLINE_xXLymphocytes < 15% of total white blood cells (WBCs) at baselineXx_NEWLINE_xXWhite blood cells (WBC) >= 2000/mm^3Xx_NEWLINE_xXWhite blood cell (WBC): >= 2000/uL (~2 x 10^9/L)Xx_NEWLINE_xXWhite blood cell count >= 4000 x 10^6 cells/LXx_NEWLINE_xXWhite blood cell (WBC) >= 2,000/mm^3Xx_NEWLINE_xXDONOR: white blood cells (WBC) 4.0-10.0 x 10^3/mm^3Xx_NEWLINE_xXWhile blood cell (WBC) ? 3.0Xx_NEWLINE_xXWhile blood cell (WBC) < 2.0 x 10^9/LXx_NEWLINE_xXWBC ? 1.5 X10³/µLXx_NEWLINE_xXWhite blood cell (WBC) ? 3,000/microLXx_NEWLINE_xXWhite blood cell (WBC) < 2000/mclXx_NEWLINE_xXWhite Blood Count > 3,000/mm3Xx_NEWLINE_xXWhite blood cell (WBC) ? 4000/µL (? 4.0 x 103/µL)Xx_NEWLINE_xXWhite Blood Cells (WBC) ? 3.0x10E9/L includingXx_NEWLINE_xXWhite blood cell (WBC) >= 2 K/microliter should be obtained with 28 days prior to randomizationXx_NEWLINE_xXWhite blood cell count (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) count >= 3,500/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3.0 x 10^9/LXx_NEWLINE_xXTotal white blood cell count (WBC) >= 2.5 x 10^3/mm^3Xx_NEWLINE_xXWhite blood count (WBC) of > 2000 ul 3Xx_NEWLINE_xXWhite blood cell count (WBC) should be lower than 30,000/mm^3 prior to initiation of cabozantinib (patients who are otherwise medically eligible for enrollment but have a WBC above 30,000/mm^3 are allowed concurrent treatment with hydroxyurea and/or 6-mercaptopurine to stabilize the WBC during the first 15 days of therapy; in these situations, hydroxyurea and/or 6-mercaptopurine will be discontinued once WBC is below 10,000/mm^3, and can be re-started if WBC again rises above 30,000/mm^3 during the first 15 days of therapy of the first cycle)Xx_NEWLINE_xXWhite blood cell (WBC) >= 2,000 /uLXx_NEWLINE_xXWhite blood cells ? 2000/µLXx_NEWLINE_xXWhite blood cells (WBC) >= 2.0Xx_NEWLINE_xXWhite blood cell count (WBC) >= 2.0Xx_NEWLINE_xXWhite blood cells (WBC) < 50,000/ul at screeningXx_NEWLINE_xXWhite blood cells greater than 1.5 x 10^3/ul (or 1,500 cells/mm^3); these results can be within last 60 days from the day of signing informed consentXx_NEWLINE_xXWhite blood cell count (WBC) >= 2,000Xx_NEWLINE_xXWhite blood cell count >= 3.0 x 10^9/LXx_NEWLINE_xXWhite blood count (WBC) >= 2.0 g/dLXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/mm^3Xx_NEWLINE_xXPatients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis prior to enrollmentXx_NEWLINE_xXWhite blood cells (WBC) < 3.5/mlXx_NEWLINE_xXWBC >/= 3,000/uLXx_NEWLINE_xXA white blood cell (WBC) count <3 × 109/L, and / or platelet count <100 × 109/L if not due to hypersplenism.Xx_NEWLINE_xXWhite blood cell count (WBC) at initiation of treatment =< 10,000/L\r\n* If WBC is > 10,000/L patients may be started on leukapheresis or an appropriate dose of hydroxyurea (to be determined by the investigators), until WBC < 10,000/L, at which time the hydroxyurea will be discontinued for 12 hours prior to enrollmentXx_NEWLINE_xXPatients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollmentXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/mLXx_NEWLINE_xXWhite blood cells (WBC) >= 2,000 cells/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3.0 K/uLXx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000/mcLXx_NEWLINE_xXAbnormal complete blood count; any of the following\r\n* Platelet count less than 75,000/ml\r\n* Hemoglobin (Hb) level less than 10 gm/dl\r\n* White blood cell (WBC) less than 3.5/mlXx_NEWLINE_xXWhite blood cell count > 3.0 k/mm3Xx_NEWLINE_xXWhite blood cell (WBC) > 3.0 K/uLXx_NEWLINE_xXWBC > 3.0 K/uLXx_NEWLINE_xXWhite blood cell count (WBC) >= 2,000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cell count (WBC) > 3,000/mm^3Xx_NEWLINE_xXWhite blood cell count (WBC) < 3500/mlXx_NEWLINE_xXTotal absolute phagocyte count (APC = %neutrophils + %monocytes) X white blood cell (WBC) is at least 1000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells (WBC) < 4,000Xx_NEWLINE_xXWhite blood cells (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 2,000Xx_NEWLINE_xXWhite blood cell (WBC) >= 3 x 10^9/LXx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cells (WBC) >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 1,500/mcLXx_NEWLINE_xXWhite blood cells >= 2,000/mcLXx_NEWLINE_xXWhite blood cell (WBC) > 3.0Xx_NEWLINE_xXSevere leukocytosis (white blood cell count [WBC] >= 20,000 cells /uL)Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,500Xx_NEWLINE_xXWhite blood cells (WBCs) >= 2000/uL, obtained within 14 days of the first dose of study drugXx_NEWLINE_xXWhite blood cell count (WBC) > 4000/mm^3Xx_NEWLINE_xXWhite blood cells (WBC) >= 3 x 10^9/L, transfusions and growth factors are allowedXx_NEWLINE_xXWhite blood cells (WBCs) < 3.0 K/UL in the past 30 daysXx_NEWLINE_xXWhite blood cell count (WBC) >= 3.0 K/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) > 2.0 k/uLXx_NEWLINE_xXWhite blood cells (WBCs) < 3.0 K/UL in the past 30 daysXx_NEWLINE_xXWhite blood cell (WBC) ? 3,500 x10^9/LXx_NEWLINE_xXWhite blood cell (WBC) >= 3,500/mm^3Xx_NEWLINE_xXTotal white blood cells (WBC) >= 4.0 x 10^3/mcL within 28 days prior to registrationXx_NEWLINE_xXExtreme hyperleukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollmentXx_NEWLINE_xXLeukocytes (white blood cells [WBC]) >= 3,000/uL (>= 2,500/uL for African-American participants)Xx_NEWLINE_xXWhite blood cells >= 3,000/microliterXx_NEWLINE_xXWhite blood cell (WBC) >= 2,500/uLXx_NEWLINE_xXLeukocytes (white blood cell [WBC]) >= 3,000/microliterXx_NEWLINE_xXWhite blood cells (WBC) within institutional limits of normal or judged to be not clinically significant by the investigatorXx_NEWLINE_xXWhite blood cell (WBC) < 2.5Xx_NEWLINE_xXPeripheral blood white blood cells (WBC) greater than 2,000 per microliter (required for collection of dendritic cell precursors)Xx_NEWLINE_xXLeukocytes >= 3,000/uL; Note: if leukopenia is idiopathic and no other significant co-morbidities exist patients will not be excluded on the basis of their white blood cell (WBC)Xx_NEWLINE_xXWhite blood cell count (WBC) >= 3,000/ulXx_NEWLINE_xXWhite blood cells (WBC) > 1500 cells/uLXx_NEWLINE_xXWhite blood cell (WBC) > 2.5 B/L (10^9/L)Xx_NEWLINE_xXAbsolute WBC (white blood cell) count ? 20 x 109/LXx_NEWLINE_xXWithin 30 days of eligibility confirmation: Leukocytes (white blood cells [WBC]) >= 3,000/uLXx_NEWLINE_xXObtained within 28 days prior to registration: White blood cell (WBC) >= 2500 cells/uLXx_NEWLINE_xXWhite blood cells >= 3,000/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 3.0 x 109/LXx_NEWLINE_xXWhite blood cell (WBC) within normal limitsXx_NEWLINE_xXWhite blood cell count >= 3.0 K/cu mmXx_NEWLINE_xXWhite blood cell count >= 3.0 K/cu mmXx_NEWLINE_xXUnacceptable hemogram: white blood cell count < 3,800/ul or > 10,500/ulXx_NEWLINE_xXWhite blood cell (WBC) count ? 20 x 10E3/µLXx_NEWLINE_xXWhite blood cell >= 2,000 /mm^3 without transfusion support > 7 days prior to registrationXx_NEWLINE_xXWhite blood cells (WBC) > 2.0 X 10^3/uLXx_NEWLINE_xXWhite blood cell (WBC) >= 4000 mm^3 or granulocyte count at least 2,000/mm^3Xx_NEWLINE_xXWhite blood count >= 1,500/mm^3Xx_NEWLINE_xXWhite blood count > 1,500/mm^3Xx_NEWLINE_xXWhite blood cell (WBC) >= 3,000/uL, performed within 28 days prior to registrationXx_NEWLINE_xXLeukopenia (white cell count < 4,000 cells/uL)Xx_NEWLINE_xXprogressive leukocytosis, defined as increasing white blood cell (WBC) count on at least 2 consecutive evaluations, at least 2 weeks apart and doubling from the nadir to ?20000/?L or absolute increase in WBC by ?50000/?L above the post-treatment nadirXx_NEWLINE_xXTotal White Blood Cell count (WBC) < 25 x 109/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed.Xx_NEWLINE_xXWhite Blood Cell Count value of <15,000 cells/?L prior to Cycle 1 Day 1.Xx_NEWLINE_xX